- Date2025-11-18
Publication of Review Result of the 10th Pharmaceutical Reimbursement Evaluation Committee of 2025
□ The Health Insurance Review & Assessment Service (HIRA, President: Kang Jung-Gu) announces the results deliberated at the 10th Drug Reimbursement Evaluation Committee in 2025
○ Deliberation Results on the Appropriateness of Reimbursement for the Requested Drugs
|
Product |
Manufacturer |
Indications |
Deliberation Results |
|
Ozempic Prefilled Pen 2 mg/1.5 mL, 4 mg/3 mL (Semaglutide) |
Novo Nordisk Pharma Co., Ltd. |
Adjunct to diet and exercise in adults with type 2 diabetes whose glycemic control is insufficient (can be used in combination with other antidiabetic agents) |
Reimbursement deemed appropriate |
|
Hyal-Flex Injection (Sodium Hyaluronate Gel Cross-Linked with Hexamethylenediamine) |
Shinpoong Pharmaceutical Co., Ltd. |
Osteoarthritis of the knee joint |
Reimbursement deemed appropriate |
|
Uplizna Injection (Inebilizumab) |
Mitsubishi Tanabe Pharma Korea Co., Ltd. |
Neuromyelitis optica spectrum disorder in adult patients positive for anti-aquaporin-4 (AQP4) antibodies |
Reimbursement deemed appropriate if accepted at or below the evaluated price |
○ Deliberation Results on the Appropriateness of Expanded Use for Risk-Sharing Agreement Drugs
|
Product |
Manufacturer |
Indications |
Deliberation Results |
|
Erleada Tablet (Apalutamide) |
Janssen Korea Ltd. |
Treatment of patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) |
Expansion of the reimbursement coverage deemed appropriate |
|
※ In accordance with Article 11-2 of the “Regulations on Standards for National Health Insurance Benefits,” the President of the Health Insurance Review and Assessment Service (HIRA) evaluates the appropriateness of drug coverage through deliberation by the Drug Benefit Evaluation Committee. The detailed coverage scope of the drug may differ from its indications, and the final evaluation results may change in the event of changes to standard items, modifications, or withdrawal (cancellation) of the approved specifications of the requested drug, or other relevant circumstances. |
- Prev
- [News] Publication of Review Result of the 9th Pharmaceutical Reimbursement Evaluation Committee of 2025
- Next
- No Next Article
